From: Polyrotaxanes as emerging biomaterials for tissue engineering applications: a brief review
No. | Type of PRX | Usage form | Type of study | Notable finding1 | Possible application | Reference |
---|---|---|---|---|---|---|
1 | Methylated PRX | Thin coating | In vitro; hMSC | H.Mf: ↓ RhoA signaling; L.Mf:↑ RhoA signaling | Modulating stem cell differentiation into adipogenic or osteogenic | [45] |
2 | Methylated PRX | Thin coating | In vitro; iPSC | H.Mf: ↑ Rac1, ↑TnT2; L.Mf:↓ Rac1, ↓TnT2 | Enhancing cardiomyocyte differentiation from iPSCs | [46] |
3 | bFGF immobilized S-PRX | Thin coating | In vitro; hMSC | H.Mf: ↑ Nanog, ↑Oct4, Cytoplasmic YAP; L.Mf:↓ Nanog, ↓Oct4, Nuclear YAP | Retention of hMSCs stemness during expansion phase | [47] |
4 | BMP2/S-PRX | Polyelectrolyte complex | In vitro; MC3T3-E1 | More tolerant to noggin deactivation, prolonged Smad signaling | Enhancing osteogenic differentiation | [50] |
5 | BMP2/S-PRX | Polyelectrolyte complex coated onto collagen scaffold | In Vivo; mouse cranial defect | Rapid bone regeneration | Potential bone graft substitute | [51] |
6 | BMP2 tethered S-PRX | Thin coating | In vitro; MC3T3-E1 | Tethering BMP2 to S-PRX enhances cell adhesion and osteogenic gene expression | Enhancing osteogenic differentiation | [52] |
7 | PEG crosslinked with aminated PRX | Porous scaffold | In vitro; primary rabbit chondrocytes | Interconnected pores in scaffold; fast water absorption and swelling of hydrogel; very good cell adhesion | Potential scaffold for cartilage regeneration | [54] |
8 | PEG crosslinked with aminated PRX and terminal ester linkages | Porous scaffold | In vitro; primary rabbit chondrocytes | Enhanced trapping of cells; tunable degradation of scaffold; enhanced GAG production | Potential scaffold for cartilage regeneration | [55] |
9 | Cholesterol-modified PRX | Porous scaffold | In vitro; primary rabbit chondrocytes | Enhanced cell adhesion; tunable degradation of scaffold; enhanced GAG production | Potential scaffold for cartilage regeneration | [56] |
10 | RGD-conjugated PRX | Injectable scaffold | In vitro; L929 mouse fibroblasts | Enhanced biocomaptibility and cell adhesion | Injectable hydrogel scaffold | [58] |
11 | RGD-conjugated PRX | Thin coating | In vitro; NIH3T3 | Rapid integrin binding; more cellular spreading | Improving ligand-cell interaction in biomaterial surfaces | [38] |
12 | VEGF-immobilized S-PRX | Thin coating | In vitro; HUVEC | L.Mf: enhanced cell proliferation; increased RhoA, Pdgf, ang1; increased endothelial network | Enhancing angiogenesis | [60] |
13 | HBEGF-immobilized S-PRX | Thin coating | In vitro; HEPG2 | H.Mf: cytoplasmic YAP retention; increased albumin secretion | Proliferating functional hepatic cells; liver tissue engineering | [61] |
14 | RGD-conjugated PRX | Thin coating | In vitro; PC12 | Increased cellular adhesion | Modulating neuronal differentiation | [63] |
15 | RGD-conjugated PRX | Thin coating | In vitro; P19CL6 | Early formation of beating cardiomyocytes | Modulating cardiomyocyte differentiation | [63] |
16 | Methylated PRX | Thin Coating | In vitro; C2C12 | Enhanced myogenesis related genes | Muscle regeneration | [64] |
17 | PRX-crosslinked collagen | Corneal membrane | In vivo; rabbit corneal injury | Enhanced remodeling of corneal epithelium and stroma | Corneal regeneration | [65] |
18 | Methylated PRX | Thin Coating | In vivo, rat subcutaneous implantation | H.Mf: induced collagen fibrillogenesis; suppressed recruitment of the macrophage | Collagen fibrillogenesis and inflammation control | [62] |